Medindia

X

ZyGEM Appoints Vice President of Business Development

Friday, January 25, 2008 General News J E 4
Advertisement
SOLANA BEACH, Calif., Jan. 24 ZyGEM Corp. Ltd., a leadingprovider of unique and innovative enzymatic solutions for DNA extraction,detection and other life sciences applications, today announced theappointment of Susan Barker as vice president of business development. Ms.Barker has more than 20 years of international business development, marketingand sales experience with biotechnology and medical supply companies,including GE Healthcare Lifesciences and Becton Dickinson. She will focus onidentifying global opportunities for expanding ZyGEM's partnerships and reachin multiple markets, including research, clinical and forensic applications.

"Susan's broad, hands-on experience in international life sciencesmarketing and business development will be invaluable as we accelerate ourproduct development and global partnering efforts," said Paul Kinnon,president and CEO of ZyGEM. "We are delighted to have recruited an individualwith her strong commercial background, exceptional reputation and successfultrack record in introducing new technologies and developing businesspartnerships, which make her a great addition to ZyGEM's leadership team."

ZyGEM develops and markets innovative solutions for life sciencesapplications that leverage the properties of unique enzymes in the company'sextensive proprietary culture collection. Its products include innovative DNAextraction and detection solutions for forensics, livestock and agriculture,basic research and clinical applications. ZyGEM's technology is based on morethan two decades of research and development on the company's exclusivecollection of microorganisms and fungi isolated from extreme environments.

"This is an exciting time to join ZyGEM, as the company prepares to expandits innovative enzyme-based technologies into new markets and additionalgeographies," said Ms. Barker. "I already see a range of opportunities inboth research and applied markets where ZyGEM's unique technologies will addsignificant value. I look forward to working with this talented and energeticteam to establish creative collaborations that will address market needs andhelp drive the rapid growth of ZyGEM."

Prior to joining ZyGEM, Ms. Barker was director, business development anddirector, strategic opportunities for GE Healthcare Lifesciences, where shedeveloped new business opportunities. Previously, she was director ofregional marketing at GE Healthcare for genomics, proteomics and drugdiscovery products, where she was involved in the successful launch of severalnew instrument and reagent platform technologies. Before joining GE, Ms.Barker was global marketing leader for high throughput screening at BectonDickinson, where she helped establish a leading market position by launchingmore than 150 new screening products in a 12-month period. Earlier in hercareer, Ms. Barker held technical support and sales positions of increasingresponsibility at Millipore Corporation. She holds a BA in Biology and MA inMicrobiology from Boston University, a post-graduate certificate in Marketingfrom Long Island University and five patents.

ZyGEM recently announced the opening of its new U.S. headquarters inSolana Beach, California.

About ZyGEM

ZyGEM Corporation Limited is a rapidly growing biotechnology company witha range of innovative enzyme-based products and technologies based on thecompany's exclusive collection of microorganisms from extreme environments.ZyGEM's technology has significant competitive advantages over existingmethods and has potential applications in a number of sizeable global markets.ZyGEM currently produces DNA extraction and detection products, molecularbiology enzymes and individual enzymes and diagnostics, serving life sciencescustomers in basic research, forensics, clinical diagnostics and agriculture.ZyGEM has facilities in New Zealand and the U.S. For more information, visith
Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
BioSeek Initiates Collaboration with Dainippon Sum...
S
SuperGen to Present at the Wachovia 2008 Healthcar...